<DOC>
	<DOCNO>NCT01920932</DOCNO>
	<brief_summary>This pilot phase II trial study well give brentuximab vedotin , combination chemotherapy , radiation therapy work treat young patient stage IIB , IIIB IV Hodgkin lymphoma . Monoclonal antibody , brentuximab vedotin , block cancer growth different way . Some block ability cancer grow spread . Others find cancer cell help kill carry cancer kill substance . Drugs use chemotherapy , etoposide , prednisone , doxorubicin hydrochloride , cyclophosphamide , dacarbazine , work different way stop growth cancer cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill cancer cell . Giving brentuximab vedotin combination chemotherapy may kill cancer cell reduce need radiation therapy .</brief_summary>
	<brief_title>Adcetris ( Brentuximab Vedotin ) , Combination Chemotherapy , Radiation Therapy Treating Younger Patients With Stage IIB , IIIB IV Hodgkin Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : - To evaluate safety brentuximab vedotin , etoposide , prednisone doxorubicin hydrochloride ( AEPA ) /cyclophosphamide , brentuximab vedotin , prednisone dacarbazine ( CAPDac ) , well efficacy ( early complete response ) 2 cycle AEPA chemotherapy high risk patient Hodgkin lymphoma ( HL ) . - To compare event-free survival high risk HL patient treat AEPA/CAPDac historical control unfavorable risk 2 arm ( UR2 ) St. Jude HOD99 study . SECONDARY OBJECTIVES : - To estimate number patient adequate response accord definition Euro-Net C1 2 cycle AEPA . - To evaluate safety Adcetris ( brentuximab vedotin ) AEPA/CAPDac regimen child high risk HL . - To describe acute hematologic , neuropathic , infectious toxicity relate transfusion requirement , growth factor support , episode febrile neutropenia hospitalization , accord National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) , version 4.0 . - To study association local failure original lymph node region volume radiation ( patterns treatment failure ) . - To assess patient-reported symptom health-related quality life child high risk HL compare treat unfavorable treatment arm St. Jude HOD99 study . OUTLINE : AEPA REGIMEN : Patients receive brentuximab vedotin day 1 , 8 , 15 , etoposide day 1 5 , prednisone three time daily ( TID ) day 1 15 , doxorubicin hydrochloride day 1 15 . Treatment repeat every 28 day 2 course absence disease progression unacceptable toxicity . CAPDac REGIMEN : Patients receive cyclophosphamide day 1 8 , brentuximab vedotin day 1 8 , prednisone TID day 1 15 , dacarbazine day 1 3 . Treatment repeat every 21-28 day 4 course absence disease progression unacceptable toxicity . Beginning 2-3 week CAPDac chemotherapy , patient lymph node go remission 2 course AEPA chemotherapy undergo radiation therapy daily , 5 day week 3-4 week . After completion study treatment , patient follow every 3 month 1 year , every 4 month 2 year , every 6 month 2 year , annually 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm , previously untreated CD30+ classical Hodgkin Lymphoma ( HL ) . ( Participants receive limited emergent radiation therapy ( RT ) steroid therapy maximum 7 day cardiopulmonary decompensation spinal cord compression eligible protocol enrollment ) . Age ≤ 18 year time enrollment ( i.e. , participant eligible 19th birthday ) . Ann Arbor stage IIB , IIIB , IVA , IVB . Adequate renal function base GFR ≥ 70 ml/min/1.73m^2 serum creatinine adjust age gender . Adequate hepatic function ( total bilirubin &lt; 1.5 x ULN age , SGOT/SGPT &lt; 2.5 x ULN age ) . Female participant postmenarchal must negative serum pregnancy test . Female male participant reproductive potential must agree use effective contraceptive method throughout duration study treatment . CD30 negative HL . Has receive prior therapy Hodgkin lymphoma , except note . Inadequate organ function describe . Inability unwillingness research participant legal guardian / representative give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pediatric cancer</keyword>
	<keyword>Hodgkin lymphoma</keyword>
	<keyword>Targeted therapy</keyword>
	<keyword>Frontline therapy</keyword>
	<keyword>Brentuximab vedotin</keyword>
	<keyword>Quality Life</keyword>
	<keyword>OEPA/COPDac</keyword>
</DOC>